MedTrace Logo

Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

NCT05291338 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 107

Last updated 2023-07-28

No results posted yet for this study

Summary

evaluate the prognostic value of genetic polymorphisms in HCC Egyptian patients undergoing TACE using lipiodol and doxorubicin.

Conditions

Interventions

DRUG

Doxorubicin

no optimal dosage of doxorubicin in TACE procedures (ranging from 30 to 75 mg/m2 up to a maximum of 150 mg/m2 ) according to tumor size

DRUG

Lipiodol

Lipiodol dose should be over 5 ml if tumor diameter is less than 5 cm, and the maximum dose will be 10 ml when the tumor develops to more than 5 cm in diameter.

Sponsors & Collaborators

  • Rehab Werida

    lead OTHER

Principal Investigators

  • Rehab H Werida, Ass Prof. · Damanhour University

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-03-31
Completion
2023-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05291338 on ClinicalTrials.gov